TSMHT
NAMS icon

Thurston Springer Miller Herd & Titak’s NewAmsterdam Pharma NAMS Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.2K Hold
1,067
– – 0.01% 535
2026
Q1 		$34.2K Hold
1,067
– – 0.01% 640
2025
Q4 		$37.4K Hold
1,067
– – 0.01% 567
2025
Q3 		$30.3K Buy
+1,067
New +$25.6K 0.06% 256

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's NAMS Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 1,067 shares worth $36.2K. The position accounts for 0.01% of the portfolio, ranked #535.

Thurston Springer Miller Herd & Titak first reported a position in NAMS in Q3 2025 and has held it in 4 quarters since. The position peaked at $37.4K in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Thurston Springer Miller Herd & Titak held 1,067 shares of NewAmsterdam Pharma worth $36.2K as of Q2 2026.
  • Thurston Springer Miller Herd & Titak left its NewAmsterdam Pharma share count unchanged in Q2 2026.
  • NewAmsterdam Pharma made up 0.01% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #535 holding.
  • Thurston Springer Miller Herd & Titak first reported a position in NewAmsterdam Pharma in Q3 2025 and has held it in 4 quarters since.
  • Thurston Springer Miller Herd & Titak's NewAmsterdam Pharma position peaked at $37.4K in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.